What H.M. Pharma Consultancy does

H.M. Pharma Consultancy (legal name Hermann Mucke Pharma Consultancy e.U.) is a Vienna, Austria-based sole proprietorship founded by Dr. Hermann Mucke that operates as an information-driven knowledge foundry for the life sciences industry. Its commercial offering centers on drug repurposing consulting, supplemented by strategic patenting, drug development program design and monitoring (pre-clinical through early clinical), OSINT-based solutions from data, and small-business advisory services for emerging life science companies. The firm maintains two proprietary internal databases — REPOSCOPE, which maps the patent and peer-reviewed literature landscape of drug repurposing from 2010 onward, and the Discontinued Drug and Candidate Database (DDCD), a machine-readable compendium of repurposable compounds — that underpin its analytical edge. Target customers are smaller and emerging life science companies and U.S./Asian firms seeking EU market entry; pricing is quote-based and not publicly disclosed.

The firm monetizes primarily through direct, project-based consulting engagements and through participation in EU-funded research consortia. It plays a leadership role within the €25 million Horizon Europe REPO4EU project (participating in 9 of 11 work packages and leading the technology assessment, drug prioritization, and CMC work package) and previously contributed to the Horizon 2020 REPO-TRIAL project on repurposed combinations for stroke and HFpEF. A 2016 co-development agreement with Excelra Knowledge Solutions extends its algorithmic repurposing capability via Excelra's GRIP platform. The firm is active in thought leadership via academic publishing, a 760+ member LinkedIn drug repurposing discussion group, conference participation, and a corporate blog, but operates with 1–10 employees, no external funding rounds, and no disclosed enterprise customer logos.

Name

H.M. Pharma Consultancy

Legal name

Hermann Mucke Pharma Consultancy e.U.

Website

https://hmpharmacon.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Vienna-based sole proprietorship providing drug repurposing consulting, strategic patenting, and EU market entry support to smaller and emerging life science companies, underpinned by proprietary databases REPOSCOPE and DDCD.

Ownership category

akta.pro rank

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Consulting Services: Direct consulting engagements providing comprehensive assistance in drug development, intellectual property strategy, and business development support. Services include design, organization and monitoring of pre-clinical and early-stage clinical drug, medical device and diagnostics development projects.
2. EU Research Project Participation: Participation in Horizon Europe and Horizon 2020 EU-funded research projects as consortium partner, leading work packages and providing expertise in technology assessment, drug prioritization, and CMC preparation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

H.M. Pharma Consultancy is a Vienna-based life science consulting firm providing integrated drug development, intellectual property (strategic patenting), drug repurposing, and EU market entry services. It operates as an information-driven knowledge foundry, leveraging OSINT, proprietary databases (REPOSCOPE and DDCD), and creative pharmacology expertise to help smaller and emerging life science companies as well as U.S. and Asian firms navigate the European market.

Product overview

H.M. Pharma Consultancy is a life science consulting firm that operates as an 'information-driven knowledge foundry.' Their core offerings center on drug repurposing consulting services, supported by two internal proprietary databases: REPOSCOPE (covering drug repurposing patent applications and peer-reviewed literature) and DDCD (Discontinued Drug and Candidate Database). The company provides Drug Development Services, Strategic Patenting Services, Solutions from Data (OSINT), and Small Business Services. They also participate in major EU-funded research projects including REPO-TRIAL (Horizon 2020) and REPO4EU (Horizon Europe), contributing to the drug repurposing framework development.

Differentiator

Problem solved

Functional benefit

Brands

• REPOSCOPE: Database covering patent and peer review documents claiming or suggesting suitability of active ingredients for drug repurposing applications
• DDCD (Discontinued Drug and Candidate Database)

Products and services

• Drug Development Services Comprehensive assistance in drug development including pre-clinical and early-stage clinical drug, medical device, and diagnostics development projects. Provides design, organization, and monitoring of development projects using a holistic, integrated approach.
• Drug Repurposing Services
• Strategic Patenting Services
• Solutions from Data (OSINT)
• Small Business Services
• EU Market Entry Services

Quantifiable outcome

• Leading role in €25 million Horizon Europe project (REPO4EU)
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• REPO4EU ConsortiumcoreStrategic or Co-development Partner · 1 September 2022Five-plus year Horizon Europe project (€25 million) developing a generic framework for drug repurposing. HMPC actively participates in 9 of 11 work packages and leads the work package on technology assessment, drug prioritization, and CMC preparation. The consortium includes 28 beneficiaries including professional societies, companies, patent attorneys, legal and ethics experts, CROs, regulators, payers, and patient representatives.
• REPO-TRIAL Horizon 2020 EU ProjectcoreStrategic or Co-development Partner · 1 January 2019Horizon 2020 EU project exploring new ways to treat acute ischemic stroke and heart failure with preserved ejection fraction (HFpEF) using drug repurposing approaches. HMPC aided in patenting of triple combinations of repurposed medications and advancement into Phase II clinical trials.
• Excelra Knowledge Solutions Pvt LtdcoreStrategic or Co-development Partner · 13 May 2016Collaboration agreement signed May 2016 for joint provision of drug repurposing services to pharmaceutical and biotech companies across Europe. Excelra brings GRIP (Global Repurposing Integrated Platform) for algorithm-driven repurposing, while HMPC provides knowledge-driven expertise in biological pathways and scientific literature context mining. The partnership aims to co-develop innovative applications of known drugs to new indications.
• LinkedIn Drug Repurposing Discussion GroupminorOthersHMPC hosts a LinkedIn discussion group on drug repurposing with over 760 members, providing a platform for informal exchange among researchers and industry professionals in the drug repurposing field.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ICON plc: Large global CRO providing clinical research, consulting, and commercialization services to pharma and biotech; overlaps with HMPC's drug development project design and monitoring but as a far larger full-service incumbent.
• Parexel International: Major global CRO offering biopharmaceutical services including clinical development, regulatory, and market access consulting; competes with HMPC on EU regulatory and market access advisory but at enterprise scale and broad portfolio.
• IQVIA: Global CRO and life science analytics powerhouse offering clinical, commercial, and consulting services across the entire pharma value chain; competes with HMPC for outsourced drug development and market access work but at vastly larger scale and breadth.

Direct peers

• Excelra Knowledge Solutions: India-headquartered data and analytics firm for life sciences; signed a 2016 co-development pact with HMPC pairing Excelra's GRIP algorithmic repurposing platform with HMPC's knowledge-driven literature and pathway expertise, making them both partners and direct comparables in drug repurposing intelligence.
• Defined Health: Boutique life science consulting firm specializing in therapeutic strategy, business development, and corporate development for biopharma; comparable in scale and niche positioning to HMPC's strategic advisory services for smaller and emerging life science companies.
• Health Advances: Boutique strategy consulting firm focused exclusively on healthcare and life sciences, advising biopharma and medtech companies on corporate strategy, asset evaluation, and commercialization; comparable to HMPC as a specialist advisor serving emerging and established life science companies.
• Alacrita Consulting: US/UK boutique life science consulting firm offering drug development strategy, due diligence, and therapeutic area advisory; highly comparable to HMPC in being a specialist advisory serving biotech and pharma clients on asset strategy and development planning.
• Halloran Consulting Group: Life science consulting firm providing drug development, regulatory, and quality strategy to biotech and pharma clients; directly comparable to HMPC in offering integrated development and regulatory advisory to emerging and mid-sized life science companies.

Emerging players

• Biovista: Drug repurposing specialist using AI-driven literature and clinical data analytics to identify new indications for existing drugs; partial overlap with HMPC's repurposing focus but operates a more productized, platform-led model rather than pure advisory.
• Healx: AI-driven drug repurposing company focused on rare diseases, combining computational biology with development expertise; partial overlap with HMPC's repurposing and rare-disease conference activity (B·Debate 2016) but operates as a developer, not an advisor.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/hmpharmacon
• LinkedInlinkedin.com/company/h.m.-pharma-consultancy

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H.M. Pharma Consultancy